Insulet Corporation
General ticker "PODD" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $20.6B (TTM average)
Insulet Corporation follows the US Stock Market performance with the rate: 51.1%.
Estimated limits based on current volatility of 1.7%: low 278.73$, high 288.31$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 3900 as of 2024
- US accounted for 74.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Supply chain disruptions, Litigation risks, Operational and conduct risks, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [197.27$, 318.45$]
- 2025-12-31 to 2026-12-31 estimated range: [211.70$, 339.90$]
Financial Metrics affecting the PODD estimates:
- Negative: with PPE of 78.8 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 14.91
- Positive: 19.35 < Shareholder equity ratio, % of 39.24 <= 42.53
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -1.77 <= -0.76
- Positive: 0.04 < Operating cash flow per share per price, % of 2.34
- Positive: Industry inventory ratio change (median), % of -1.22 <= -0.18
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.93 > 6.04
Short-term PODD quotes
Relationship graph
Long-term PODD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,305.30MM | $1,697.10MM | $2,071.60MM |
| Operating Expenses | $1,267.70MM | $1,477.10MM | $1,762.70MM |
| Operating Income | $37.60MM | $220.00MM | $308.90MM |
| Non-Operating Income | $-27.80MM | $-5.40MM | $-8.70MM |
| Interest Expense | $36.00MM | $36.20MM | $42.70MM |
| R&D Expense | $180.20MM | $205.00MM | $219.60MM |
| Income(Loss) | $9.80MM | $214.60MM | $300.20MM |
| Taxes | $5.20MM | $8.30MM | $-118.10MM |
| Profit(Loss)* | $4.60MM | $206.30MM | $418.30MM |
| Stockholders Equity | $476.40MM | $732.70MM | $1,211.60MM |
| Inventory | $346.80MM | $402.60MM | $430.40MM |
| Assets | $2,251.10MM | $2,588.20MM | $3,087.70MM |
| Operating Cash Flow | $119.00MM | $145.70MM | $430.30MM |
| Capital expenditure | $157.30MM | $75.60MM | $124.90MM |
| Investing Cash Flow | $-191.10MM | $-119.40MM | $-146.20MM |
| Financing Cash Flow | $-40.30MM | $-13.60MM | $-28.10MM |
| Earnings Per Share** | $0.07 | $2.96 | $5.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.